company background image
TLX logo

Telix Pharmaceuticals ASX:TLX Stock Report

Last Price

AU$16.46

Market Cap

AU$5.8b

7D

-8.4%

1Y

51.1%

Updated

13 Jun, 2024

Data

Company Financials +

Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$5.8b

TLX Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.

TLX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Telix Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Telix Pharmaceuticals
Historical stock prices
Current Share PriceAU$16.46
52 Week HighAU$19.06
52 Week LowAU$8.20
Beta2.43
1 Month Change9.44%
3 Month Change36.26%
1 Year Change51.15%
3 Year Change186.76%
5 Year Change1,211.55%
Change since IPO2,037.66%

Recent News & Updates

Recent updates

Shareholder Returns

TLXAU BiotechsAU Market
7D-8.4%-1.5%-0.7%
1Y51.1%-0.5%8.2%

Return vs Industry: TLX exceeded the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: TLX exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is TLX's price volatile compared to industry and market?
TLX volatility
TLX Average Weekly Movement7.4%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: TLX's share price has been volatile over the past 3 months.

Volatility Over Time: TLX's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015423Chris Behrenbruchtelixpharma.com

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.

Telix Pharmaceuticals Limited Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
TLX fundamental statistics
Market capAU$5.78b
Earnings (TTM)AU$31.68m
Revenue (TTM)AU$576.27m

182.5x

P/E Ratio

10.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLX income statement (TTM)
RevenueAU$576.27m
Cost of RevenueAU$209.33m
Gross ProfitAU$366.95m
Other ExpensesAU$335.27m
EarningsAU$31.68m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.09
Gross Margin63.68%
Net Profit Margin5.50%
Debt/Equity Ratio6.1%

How did TLX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.